
Cuprior - European Medicines Agency (EMA)
Cuprior is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cuprior is used in patients who cannot take D-penicillamine, another medicine for this condition.
Home - Cuprior
2023年2月2日 · Select your location below to view the Cuprior ® Patient Information Leaflet (PIL) in your language.
Cuprior is a medicine used to treat Wilson’s disease that contains the active substance trientine. Wilson’s disease is an inherited condition in which the body cannot transport copper around the body in the normal way or remove copper in the normal way as …
Orphalan announces FDA approval of Cuvrior™ for the treatment …
2022年5月2日 · Orphalan commercializes its trientine tetrahydrochloride product in Europe under the name of Cuprior® and expects to launch Cuvrior™, which has been granted Orphan Drug Designation by the FDA, in the US by early 2023.
Cuprior 150 mg film-coated tablets - Summary of Product
2024年4月30日 · Cuprior is for oral use. The film-coated tablets should be swallowed with water. The scored film-coated tablet can be divided in two equal halves, if required, to provide a more precise dose or facilitate administration.
三亚乙基四胺 - 维基百科,自由的百科全书
四盐酸曲恩汀(品牌名 Cuprior)于2017年9月在欧盟获准用于医疗用途,适用于治疗对D-青霉胺疗法不耐受的成人、青少年和5岁或以上儿童的威尔森氏病。 [ 17 ]
威尔逊病青霉胺替代药!FDA批准Cuvrior(四盐酸盐曲恩汀) - 知乎
据Orphalan SA 公司于5月2日宣布, 美国食品药品监督管理局 (FDA)已批准Cuvrior (trientine tetrahydrochloride,四盐酸盐曲恩汀),用于治疗患有脱铜且对青霉胺耐受的成人稳定型威尔逊病。 预计将于2023年初上市。 此前,四盐酸盐曲恩汀已在欧盟获批,名为Cuprior。 Cuvrior 含有曲恩汀,这是一种 铜螯合剂,可通过形成稳定的复合物消除体内吸收的铜,然后通过尿液排泄消除。 曲恩汀还在肠道中螯合铜,减少铜的吸收。 该批准基于随机、非盲的 3 期 CHELATE 研究 …
What is Cuprior and what is it used for? Cuprior is a medicine used to treat patients aged 5 years and older with Wilson’s disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage.
Cuprior is indicated for the treatment of Wilson’s disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy. Treatment should only be initiated by specialist physicians with experience in the management of Wilson’s disease.
Cuprior 治疗威尔逊病 - 知乎 - 知乎专栏
Cuprior 用于治疗5岁及以上的成人、青少年和儿童的威尔逊病,适用于对D-青霉胺疗法不耐受的患者。 每片 Cuprior 含有299.61毫克的…